Showing 5021-5030 of 5554 results for "".
- Cosmetic Surgery Forum Names 2014 Award Winnershttps://practicaldermatology.com/news/cosmetic-surgery-forum-names-award-winners/2459049/Cosmetic Surgery Forum, taking place later this week at the Palazzo Resort and Casino in Las Vegas, will recognize Dr. Carl Thornfeldt and Dr. Haines Ely for their respective career achievements and contributions to the field of cosmetic dermatology. Receiving the Innovators in Dermatolog
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n
- Gabrielle Rios, Founder of TruInject, Wins Stevie Award for Startupshttps://practicaldermatology.com/news/20141119-gabrielle_rios_founder_of_truinject_wins_stevie_award_for_startups/2459058/Gabrielle Rios, chief executive officer of TruInject Medical Corporation, received the Bronze Award at the 2014 Stevie Awards for Women in Business. The award was presented in the category of Startup of the Year. The Stevie® Awards for Women in Business honors women executives, entrepreneurs, a
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Foamix Receives USPTO Patents for Topical Tetracyclineshttps://practicaldermatology.com/news/20141113-foamix_receives_uspto_patents_for_topical_tetracyclines/2459066/Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additi